Masinde 1998.
Methods | Randomized controlled trial Generation of allocation sequence: not stated Allocation concealment: not stated Blinding: 'blinded', not explicitly stated to be double blind Inclusion of all randomized participants: 69/85 (81.2%) received all 3 doses Length of follow up: 3 months after third dose |
|
Participants | 85 adults Inclusion criteria: age 18 to 50 years; resident in study area Exclusion criteria: thrombocytopenia; granulocytopenia, anaemia; pregnancy; gastritis; abnormal liver function; pelvic mass; cholelithiasis; hypertension; asthma; respiratory infection; heart murmur; chest pain |
|
Interventions | 1. 3 doses of SPf66 given at 3 to 4 month intervals either intramuscularly (27 participants) or subcutaneously (28 participants)
2. Hepatitis B Engerix, given intramuscularly (30 participants) Quinine (10 mg/kg 3 times a day for 3 days) and doxycycline (100 mg twice a day for 7 days) given 1 week after doses 2 and 3 |
|
Outcomes | 1. Prevalence of parasitaemia, 2 and 3 months after immunization 2. Infection with specific Plasmodium falciparum types as detected by polymerase chain reaction (PCR) | |
Notes | Location: Siaya district, Nyanza province, Kenya, a highly endemic area with EIR of 6 to 30 infective bites per month during April to August Date: 1995 Method of surveillance: weekly blood slides |